Use of Myrtol standardized in the treatment of children with acute rhinosinusitis

Karpova E.P.; Tulupov D.A.; Emel’yanova M.P.

doi:https://doi.org/10.17116/otorino201681147-50

Karpova E.P.

Kafedra detskoĭ otorinolaringologii Rossiĭskoĭ meditsinskoĭ akademii poslediplomnogo obrazovaniia

Tulupov D.A.

Kafedra detskoĭ otorinolaringologii Rossiĭskoĭ meditsinskoĭ akademii poslediplomnogo obrazovaniia

Emel’yanova M.P.

Russian Academy of Post-Graduate Education, Moscow, Russia, 125993

Use of Myrtol standardized in the treatment of children with acute rhinosinusitis

Authors:

Karpova E.P., Tulupov D.A., Emel’yanova M.P.

More about the authors

Journal: Russian Bulletin of Otorhinolaryngology. 2016;81(1): 47‑50

DOI: 10.17116/otorino201681147-50

Read: 5172 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Karpova EP, Tulupov DA, Emel’yanova MP. Use of Myrtol standardized in the treatment of children with acute rhinosinusitis. Russian Bulletin of Otorhinolaryngology. 2016;81(1):47‑50. (In Russ.)
https://doi.org/10.17116/otorino201681147-50

Подписка 2026 Вестник оториноларингологии (Russian Bulletin of Otorhinolaryngology)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Abstract:

The present study included 60 children at the age from 6 to 10 years undergoing a course of out-patient and in-patient treatment of acute rhinosinusitis (ARS). Thirty of these patients were given Myrtol standardised in the dose of 120 mg thrice daily for 7 days, in addition to traditional therapy.With convincing objective data for acute bacterial rhinosinusitis (in accordance with the criteria of EP3OS 2012), antibacterial preparations were prescribed to the children. The remaining patients received either conventional (symptomatic, irrigation) therapy or systemic antimicrobial agents. The analysis of characteristics of the visual-analog scale reflecting the severity of rhinorrhea, basal congestion, and coughing has demonstrated a significant (р<0,05) difference between the two groups of children in terms of manifestations of the clinical symptoms within days 7 and 14 after the onset of the treatment. For basal congestion, the difference was apparent as soon as day 3 after the beginning of therapy. The duration of the treatment with intranasal vasoconstrictive medications used for symptomatic therapy by the patients given Myrtol standardized was 2.2±0.4 days in comparison with 3.6±0.5 days in the control group. None of the patients treated with GeloMyrtol exhibited any adverse reaction attributable to the action of the medication in being studied. The study has demonstrated that using Myrtol standardized for the treatment of the uncomplicated forms of acute rhinosinusitis in children is clinically effective, safe, and convenient method for the management of ARS in children. And it can be recommended for the wide practical application.

Keywords:

acute rhinosinusitis

children

Myrtol standardized

Authors:

Karpova E.P.

Kafedra detskoĭ otorinolaringologii Rossiĭskoĭ meditsinskoĭ akademii poslediplomnogo obrazovaniia

Tulupov D.A.

Kafedra detskoĭ otorinolaringologii Rossiĭskoĭ meditsinskoĭ akademii poslediplomnogo obrazovaniia

Emel’yanova M.P.

Russian Academy of Post-Graduate Education, Moscow, Russia, 125993

Close metadata

References:

Fokkens W, Lund V, Mullol J, Bachert C, Alobid I, Baroody F, Cohen N, Cervin A, Douglas R, Gevaert P, Georgalas C, Goossens H, Harvey R, Hellings P, Hopkins C, Jones N, Joos G, Kalogjera L, Kern B, Kowalski M, Price D, Riechelmann H, Schlosser R, Senior B, Thomas M, Toskala E, Voegels R, Wang de Y, Wormald J. European position paper on rhinosinusitis and nasal polyps 2012 (EP³OS). Rhinology. 2012;50:23:1-299. doi: 10.4193/rhino50e2.
Herløv-Nielsen H, Højby N. Sinusitis is common in small children. Ugeskr Laeger. 2010;172:48:3320-3325.
Cronin MJ, Khan S, Saeed S. The role of antibiotics in the treatment of acute rhinosinusitis in children: a systematic review. Arch Dis Child. 2013;98:4:299-303. doi: 10.1136/archdischild-2012-302983.
Babar-Craig H, Gupta Y, Lund VJ. British Rhinological Society audit of the role of antibiotics in complications of acute rhinosinusitis: a national prospective audit. Rhinology. 2010;48:3:344-347. doi: 10.4193/rhin09.130.
Hansen FS, Hoffmans R, Georgalas C, Fokkens WJ. Complications of acute rhinosinusitis in The Netherlands. Fam Pract. 2012;29:2:147-153. doi: 10.1093/fampra/cmr062.
Meltzer EO, Hamilos DL. Rhinosinusitis diagnosis and management for the clinician: a synopsis of recent consensus guidelines. Mayo Clin Proc. 2011;86:5:427-443. doi: 10.4065/mcp.2010.0392.
Karpova E.P., Tulupov D.A. O vozmozhnosti nebulaizernoi terapii v lechenii ostrykh rinosinusitov u detei. Rossiiskaya otorinolaringologiya. 2013;65:4:160-163.
Behrbohm H, Kaschke O, Sydow K. Effect of the phytogenic secretolytic drug Gelomyrtol forte on mucociliary clearance of the maxillary sinus. Laryngorhinootologie. 1995;74:12:733-737.
Zimmermann T, Seiberling M, Thomann P, Karabelnik D. The relative bioavailability and pharmacokinetics of standardized myrtol. Arzneimittelforschung. 1995;45:11:1198-1201.
Gramann J, Hippeli S, Dornisch K, Rohnert U, Beuscher N, Elstner EF. Antioxidant Properties of Essential Oils, Arzneim. Forsch. Drug Res. 2000;50:1:135-139.
Beuscher N, Kietzmann M, Bien E, Champeroux P. Interference of myrtol standardized with inflammatory and allergic mediators. Arzneimittelforschung. 1998;48:10:985-989.
Rantzsch U, Vacca G, Dück R, Gillissen A. Anti-inflammatory effects of Myrtol standardized and other essential oils on alveolar macrophages from patients with chronic obstructive pulmonary disease. Eur J Med Res. 2009;14(suppl 4):205-209.
Federspil P, Wulkow R, Zimmermann T. Effects of standardized Myrtol in therapy of acute sinusitis — results of a double-blind, randomized multicenter study compared with placebo. Laryngorhinootologie. 1997;76:1:23-27.
Sengespeik HC, Zimmermann T, Peiske C, de Mey C. Myrtol standardized in the treatment of acute and chronic respiratory infections in children. A multicenter post-marketing surveillance study. Arzneimittelforschung. 1998;48:10:990-994.